Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Small molecules

a technology of ubiquitin ligase and small molecules, which is applied in the field of small molecules, can solve the problems of incomplete blockade of enzyme activity, ineffective e3 ligase inhibition, and failure to recapitulate genetic knockout or knockdown, so as to increase the flux of compound across the skin and control the delivery of compound

Inactive Publication Date: 2022-04-28
UNIVERSITY OF DUNDEE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0058]Powders and sprays can contain, in addition to the PROTAC compounds of this invention, excipients such as lactose, talc, silicic acid, aluminium hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons. Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

Problems solved by technology

However, E3 ligases do not comprise deep and “druggable” active sites for binding to small molecules.
Blockade of E3 ligase activity therefore requires targeting of protein-protein interactions (PPIs), and the often extended, flat and solvent-exposed PPI surfaces make it a challenge for drug design.
This poses limitations, such as the need to use high inhibitor concentrations, which can lead to off-target effects and cytotoxicity, and incomplete blockade of enzyme activity.
As a result, E3 ligase inhibition may be ineffective or fail to recapitulate genetic knockout or knockdown.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Small molecules
  • Small molecules
  • Small molecules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0100]While the making and using of various embodiments of the present invention are discussed in detail below, it should be appreciated that the present invention provides many applicable inventive concepts that can be embodied in a wide variety of specific contexts. The specific embodiments discussed herein are merely illustrative of specific ways to make and use the invention and do not delimit the scope of the invention.

[0101]To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as “a”, “an” and “the” are not intended to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims.

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
structureaaaaaaaaaa
lengthaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

Compounds having the general structure A-L-B are presented wherein A and B are independently an E3 ubiquitin ligase protein binding ligand compound of formula 1A or 1B. Pharmaceutical compositions comprising these compounds and methods of use are also presented.

Description

FIELD OF THE INVENTION[0001]This invention relates to small molecule E3 ubiquitin ligase protein binding ligand compounds, and to their utility in PROteolysis Targeted Chimeras (PROTACs), as well as processes for the preparation thereof, and use in medicine. This invention particularly relates to PROTACs capable of inducing auto-ubiquitination of E3 ubiquitin ligases and triggering their subsequent proteasomal degradation.BACKGROUND OF THE INVENTION[0002]E3 ubiquitin ligases are emerging as attractive targets for small-molecule modulation and drug discovery. E3s bring a substrate protein and ubiquitin in close proximity to each other to catalyze the transfer of a ubiquitin molecule to the substrate. Substrate ubiquitination can trigger different cellular outcomes, of which one of the best characterized is poly-ubiquitination and subsequent proteasomal degradation. The human genome comprises >600 predicted E3 ligases that play important roles in normal cellular physiology and dise...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D417/14
CPCC07D417/14C07K5/06191C07K5/06034C07K5/06165A61P35/00
Inventor CIULLI, ALESSIOMANIACI, CHIARAHUGHES, SCOTT J.TESTA, ANDREA
Owner UNIVERSITY OF DUNDEE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products